Citius Oncology closes $9 million equity offering Sep 10, 2025 04:30PM
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement Sep 10, 2025 04:30PM
Citius Oncology prices $9 million offering at $1.75 per share Sep 9, 2025 08:30AM
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement Sep 9, 2025 08:30AM
Citius Oncology closes $9 million public offering Jul 17, 2025 04:30PM


Jul 17, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Public Offering
Jul 17, 2025 04:30PM Citius Oncology Announces Closing of $9.0 Million Public Offering
Jul 16, 2025 09:15AM Citius Oncology prices $9 million public offering at $1.32 per share
Jul 16, 2025 09:15AM Citius Oncology Announces Pricing of $9.0 Million Public Offering
Aug 12, 2024 04:22PM Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
Aug 9, 2024 07:30AM TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
Aug 5, 2024 08:02AM Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology
Aug 5, 2024 08:00AM TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
Aug 5, 2024 08:00AM Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
Oct 24, 2023 07:31AM Citius Pharmaceuticals (CTXR) to Merge Wholly Owned Subsidiary with TenX Keane Acquisition (TENK) to Form Publicly Listed Citius Oncology, Inc.
Oct 24, 2023 07:30AM Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Jun 13, 2023 08:30AM Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023
Mar 30, 2023 08:32AM Citius Pharmaceuticals (CTXR) Advances Efforts to Spin Off I/ONTAK into Standalone Company
Mar 30, 2023 08:30AM Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company
Nov 30, 2021 08:26AM UPDATE: Maxim Group Starts Citius Pharmaceuticals (CTXR) at Buy